🔥 Lose fat
6 mechanistic pathways · 109 options
Fat loss is not one mechanism, and that is why people stall. An appetite drug does nothing for someone who already eats little and has a dead metabolic rate; a mitochondrial uncoupler does nothing for someone who cannot stop eating at 9pm. Find the pathway that matches your actual failure point, then pick from inside it.
The pathways
Appetite & satiety signaling
Incretin and amylin receptors in the hypothalamus and brainstem set how much food it takes to feel done, and how fast the stomach empties. Engage them and intake falls without willpower being involved. This is the most clinically developed pathway in the whole Vault — and the least interesting one if your intake is already low.
Mitochondrial & metabolic reprogramming
This is the pathway Cam means when he says stretch and extrapolate. Instead of eating less, you change how much energy the cell burns and how efficiently it burns it — mitochondrial biogenesis, uncoupling, NAD+ availability, PGC-1α. Almost nothing here has a human fat-loss trial. The mechanisms are well characterized and the rodent data is often striking. That gap is the opportunity and the risk in one.
Direct lipolysis & adrenergic drive
Skip the brain and the mitochondrion and act on the fat cell itself. β-adrenergic receptors on adipocytes trigger hormone-sensitive lipase; GH fragments do something similar without the glucose consequences of full GH. Fast-acting, and the same receptors sit on your heart, which is the entire safety story of this pathway.
Substrate partitioning & insulin control
Where a calorie goes matters as much as how many arrive. Chronically elevated insulin keeps hormone-sensitive lipase switched off — you cannot mobilize fat you are simultaneously storing. Improve glucose disposal and you change the destination of the same food.
Thyroid & thermogenic substrate
Thyroid hormone sets the floor under resting metabolic rate. If that floor has dropped — from dieting, from illness, from age — no amount of appetite suppression fixes the arithmetic. This pathway is about the denominator, and it is the one most worth testing before treating.
Lean-mass protection while cutting
Fat loss that takes muscle with it lowers your metabolic rate and guarantees the regain. Any aggressive deficit — and every GLP-1 — needs an answer to this, and it belongs in the fat-loss plan rather than as an afterthought once the scale has moved.
Test before you choose a pathway
Every route below can be argued for on mechanism. Only bloodwork tells you which one is actually your problem — and picking the wrong pathway is the most common reason someone concludes "none of this works". Across all 6 pathways, these are the 21 markers worth having in front of you first.
Ordered together:
📉 Insulin Resistance Deep Dive🍭 Metabolic Health & Prediabetes🌡️ Adrenal & Cortisol Axis🦋 Thyroid — First Look💉 On a GLP-1 (Semaglutide / Tirzepatide)What actually decides this outcome, in order of size
The number on the scale is four compartments wearing one label, and most of the disagreements on this goal are disagreements about which compartment moved. Ranked by how much of the outcome each one owns:
- Which tissue the change came from, because body mass does not say. Fat, lean tissue, glycogen with its bound water, and gut contents all register identically. This is not a technicality: how anti-obesity medication affects skeletal muscle mass is confounded by the measurement itself, which has been written up as a methodological problem rather than a debate McMath 2025. A page that reports one number is reporting the sum of four.
- What happens to resting metabolic rate, which falls for two separable reasons. Losing tissue lowers it because there is less tissue, and there is an additional adaptive component beyond that; both contributions have been quantified in the same analysis Martin 2022. Those two have different implications, because only one of them is addressable by keeping the tissue.
- Whether the muscle compartment is being defended. Protein intake and resistance training have a meta-analysis and meta-regression behind them for lean mass during training Morton 2018, and the specific reason a myostatin-pathway antibody was combined with an incretin agonist in a randomized trial is that lean-mass loss on this goal is a measurable known problem Heymsfield 2026. Lean-mass protection while cutting is the pathway for it.
- Whether there is a medical driver that changes the whole picture. An untreated thyroid problem, a medication with a known weight effect, an androgenic and insulin-resistant pattern, or untreated sleep apnea each change what is possible before anything on this shelf is opened. Thyroid hormone therapy for subclinical hypothyroidism has a randomized trial in older adults that is worth reading before assuming a treatment is warranted Stott 2017.
- Which of six mechanisms you are actually buying, because they are not interchangeable. Reviews of this field now separate appetite regulation from energy expenditure, fat oxidation and lean-mass preservation explicitly Christoffersen 2022, which is the same split the six pathways below use.
- The compounds, last, and their effect sizes are orders of magnitude apart. A prescription incretin agonist with cardiovascular outcome data Lingvay 2024 and a catechin extract whose effect on resting metabolic rate and respiratory quotient has been systematically reviewed Rondanelli 2021 are not the same kind of object, and listing them on one page does not make them comparable.
The order to run these in, and what has to be true first
Establish what is being measured, exclude the medical drivers, protect the muscle compartment, and only then choose a mechanism. Nothing below is a dietary instruction; the diet is not this site's estate and a goal page that wrote one would be pretending to knowledge of a reader it has never met.
- Fix the measurement before the intervention. One method, one set of conditions, recorded. Body mass and waist circumference at a marked landmark, plus one strength measure such as grip dynamometry or a fixed five-repetition load. The strength number is what turns a mass trend into a statement about composition without a scan, and it is the read-out the lean-mass literature implies Heymsfield 2026 McMath 2025.
- One requisition, before anything. TSH (Thyroid-Stimulating Hormone) with Free T4 (Thyroxine) and Free T3 (Triiodothyronine), HbA1c (Hemoglobin A1c) with Fasting Insulin, Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) with ApoB (Apolipoprotein B), Comprehensive Metabolic Panel (CMP), Complete Blood Count (CBC) with Differential and Ferritin. This is a set of exclusions, not a shopping list, and two of the six pathways below are only appropriate if it comes back a particular way.
- Speak to a clinician first if the difficulty is the relationship with food rather than its physiology. If eating is a source of distress, if it is already restricted, if it feels out of control, or if weight has become the main way you judge yourself, then the right next step is a clinician who works with eating. That is not a hedge and it is not a smaller step than the rest of this page; it is the honest boundary of what a pharmacology page can address.
- Resistance training and adequate protein from the beginning, not afterwards. The meta-analytic base for protein and training on lean mass is the strongest thing on this goal that requires no prescription Morton 2018, and Creatine, Whey Protein (RecoveryPro) and Essential Amino Acids belong here rather than in a fat-loss stack.
- If the panel showed insulin resistance, take the partitioning route. Substrate partitioning & insulin control and Metabolic health & insulin sensitivity, where Metformin, Myo-Inositol and Berberine sit. Where a calorie goes is a different question from how many arrive.
- If the panel showed a thyroid problem, that is a clinical conversation and a specific pathway. Thyroid & thermogenic substrate is about substrate and conversion, and Ashwagandha raised thyroid hormones in a small randomized trial in subclinical hypothyroidism Sharma 2018, which also makes it a poor idea in the opposite situation.
- The prescription arm is prescribed, monitored, and has its own page. Appetite & satiety signaling and Incretin & satiety signaling. Nothing there is a self-directed purchase, and the cardiovascular outcome analysis is the reason to prefer an agent with hard endpoints Lingvay 2024.
- The adrenergic and mitochondrial arms last, and know which one you are in. Direct lipolysis & adrenergic drive acts on the fat cell and on the heart with the same receptor family; Mirabegron is the exception that acts at a third receptor and has human imaging behind the mechanism Dąbrowska 2023. Mitochondrial & metabolic reprogramming is where the mechanisms are best characterized and the human fat-loss trials are largely absent, which is stated on that page rather than hidden.
What gets bought for this that cannot move it
The category that fails structurally is the thermogenic blend sold on a resting metabolic rate argument. Catechins and caffeine do measurably change resting metabolic rate and respiratory quotient, and the systematic review of that effect is the right place to see its size Rondanelli 2021. The problem is what the size is next to the compartment question above it: an intervention that changes energy expenditure by a small percentage is being asked to compete with a measurement whose noise is larger than the effect. It is not that the mechanism is false. It is that the read-out cannot see it.
The scale is the surrogate, and on this goal it is the most trusted instrument in the room. Weight integrates fat, lean tissue, glycogen with its bound water, and gut contents, and the confounding is serious enough that measuring muscle change during pharmacotherapy has been treated as a methodological problem in its own right McMath 2025. Two people can lose the same mass and be in opposite positions. That is why waist, strength and a blood panel appear in the read-out below and body mass appears beside them rather than alone.
The lean-mass cost of any energy deficit is the part most often left out. It is measurable, it is the reason a trial combined a myostatin-pathway antibody with an incretin agonist Heymsfield 2026, and the free version of the answer is loading the muscle while the deficit is happening rather than after the mass has gone Morton 2018. Resting metabolic rate falls for both a tissue reason and an adaptive one Martin 2022, and only the first is something training can defend.
And the reader this goal is most likely to harm is the one whose difficulty is with food itself rather than with its physiology. If eating is a source of distress, if it is already restricted, if it feels out of control, or if this goal has become the main way you judge yourself, then the pharmacology on these six pathways is the wrong instrument and the right step is a clinician who works with eating. If the goal underneath is different again, so is the page: strength and shape rather than mass is Build muscle & strength, fatigue is Energy & fatigue, and metabolic health independent of weight is Metabolic health & insulin sensitivity. And subclinical thyroid results in older adults did not benefit from treatment in a randomized trial Stott 2017, so an abnormal number is a conversation rather than an automatic prescription.
How you would know it was working, on a real read-out and a real timescale
This page makes two predictions. Waist circumference and a strength measure will disagree with body mass often enough to change decisions, and the disagreement is the information; and HbA1c (Hemoglobin A1c) with Fasting Insulin will move on an effective metabolic intervention whether or not the scale does, which is the case where the scale is the misleading number rather than the honest one.
- Waist circumference at a marked landmark, plus one strength measure, weekly, same conditions. Mark the site, because a centimeter of landmark drift is larger than a month of change. Falling strength alongside falling mass means the loss is not the compartment you wanted Heymsfield 2026.
- HbA1c (Hemoglobin A1c) with Fasting Insulin at baseline and 12 weeks. Twelve weeks because glycated hemoglobin integrates over the circulating red cell population and a shorter interval reports the assay's noise rather than your change.
- TSH (Thyroid-Stimulating Hormone) with Free T4 (Thyroxine) and Free T3 (Triiodothyronine) at baseline, and again only if there is a reason. Thyroid hormones fall during sustained energy restriction as an expected physiological response, so a mid-deficit panel is hard to interpret and easy to over-treat Stott 2017.
- Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) with ApoB (Apolipoprotein B) at baseline and 6 months. Apolipoprotein B is the lipid read-out that survives a large change in body composition better than cholesterol mass does, and the cardiovascular endpoint on this goal was not explained by the glycemic one Lingvay 2024.
- Ferritin, Vitamin B12 and Vitamin D (25-Hydroxy) once at six months on any sustained intervention. Reduced intake reduces micronutrient intake with it, and these three become symptomatic first.
What will fool you. The first fortnight of almost any change moves glycogen and its bound water, so early mass change overstates fat change in both directions. A single high-carbohydrate day or a salty meal moves the same compartment. Menstrual cycle phase moves it too, which is why a monthly comparison should be phase-matched. Resting metabolic rate estimated from an equation is an estimate of a population, not a measurement of you, and the adaptive component it is supposed to detect is precisely what equations cannot see Martin 2022. Thermic agents produce a heart-rate and subjective response that feels like efficacy and is not Rondanelli 2021. And a body-composition scan done on a different machine is a different number, so keep the machine constant or do not compare.
Sources read for these sections
- Martin A. Tissue losses and metabolic adaptations both contribute to the reduction in resting metabolic rate following weight loss. International Journal of Obesity 2022 · PMID 35181758
- Christoffersen BO. Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. Obesity (Silver Spring) 2022 · PMID 35333444
- McMath A. Understanding Impact of Anti-Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods. Obes Rev 2025 · PMID 41287517
- Heymsfield SB, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine 2026 · PMID 41772149
- Morton RW. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. British Journal of Sports Medicine 2018;52(6):376-384 · PMID 28698222
- Stott DJ, et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. New England Journal of Medicine 2017 · PMID 28402245
- Sharma AK, et al. Efficacy and Safety of Ashwagandha Root Extract in Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial. The Journal of Alternative and Complementary Medicine, 2018 · PMID 28829155
- Rondanelli M. Effect of Acute and Chronic Dietary Supplementation with Green Tea Catechins on Resting Metabolic Rate, Energy Expenditure and Respiratory Quotient: A Systematic Review. Nutrients 2021 · PMID 33671139
- Dąbrowska AM, Dudka J. Mirabegron, a Selective beta3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug. Journal of Clinical Medicine 2023 · PMID 37959362
- Lingvay I. Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care 2024 · PMID 38907684
You have the pathways. Here is the stack.
The Fat Loss Blueprint names the one compound I would start with in each of these 6 pathways, what it was chosen over, and why — plus 20 options to swap in or stack on top, every one of them priced and linked.
Open The Fat Loss Blueprint →You know the goal. Skool has the plan.
Every pathway above is one arm of The Lose fat Blueprint. The members' version has the sequence they run in, what stacks with what, and the markers that tell you to keep going or stop — alongside the Bloodwork Protocols.
Open The Lose fat Blueprint in Skool →$10/mo, cancel anytime.
← Open Lose fat in the interactive Vault · All 21 goals
Frequently asked questions
This goal is broken into 6 distinct mechanistic pathways — Appetite & satiety signaling; Mitochondrial & metabolic reprogramming; Direct lipolysis & adrenergic drive; Substrate partitioning & insulin control and others — across 109 compounds and supplements. Each pathway is a different argument about how the body gets there, so the useful question is which one matches where you are actually stuck.
The one that matches your actual limitation, which bloodwork usually settles faster than guessing. An appetite drug does nothing for someone who already undereats, and a thyroid intervention does nothing if your thyroid is fine. Each pathway page lists the markers that tell you whether it is your problem.
No. The 6 pathways are listed in mechanistic order, not by strength of evidence, and neither are the 109 options inside them. A lot of what works in this space has never had the trial run, and sorting by trial count would bury exactly the compounds you came looking for.
Where this goes next
Everything above is the free case for Lose fat. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.